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The use of hormonal therapy with radiotherapy for prostate
cancer: analysis of prospective randomised trials
AR Gottschalk1 and M Roach III*,1
1Department of Radiation Oncology and the Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero St., H-1031,
San Francisco, CA 94115, USA
In 1901, Wilhelm Conrad Ro¨ntgen won the Nobel prize in Physics for his discovery of the Ro¨ntgen rays or, as he himself called them,
X-rays. In 1966, Dr Charles Brenton Higgins won the Nobel Prize in Medicine for his breakthroughs concerning hormonal treatment
of prostatic cancer. After 31 years, in 1997, the first prospective randomised trials of the combination of hormonal therapy and
radiation therapy were published, showing increased survival when compared to radiation therapy alone for patients with prostate
cancer. Since 1997, many investigators have published trials combining hormonal and radiation therapy for prostate cancer. This
minireview will address the largest and most influential of these trials, and attempt to guide physicians in selecting the appropriate
patients for this combined approach.
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Patients with prostate cancer are usually divided into risk groups
in order to determine their chance of recurrence and appropriate
therapy. Although there are many methods to define the risk
groups, they all separate patients into low-risk, intermediate-risk
and high-risk categories. Recurrences after therapy can be defined
as local (prostate only), regional (lymph nodes) or distant (bone
metastasis).
Low-risk patients do extremely well with treatment and have a
low risk of a recurrence locally, regionally or distantly. It is
generally accepted that these patients do not benefit from the
addition of hormonal therapy, although hormonal therapy in low-
risk patients has not been formally tested. Intermediate-risk
patients have a greater potential for local-regional recurrences and
distant recurrences. High-risk patients confront a significant risk
of distant recurrence. While local-regional failure can occur in
high-risk patients, distant disease is the main problem for these
patients.
In this article, we will discuss prospective randomised trials
demonstrating that intermediate-risk patients benefit from short-
term androgen deprivation and high-risk patients benefit from
long-term androgen deprivation (LTAD). These observations
suggest that short-term androgen deprivation reduces the risk of
a local-regional recurrence, while LTAD is effective in treating
systemic disease.
EORTC
As published in the New England Journal of Medicine in 1997
(Bolla et al, 1997), the EORTC reported a study of improved
survival in patients with locally advanced prostate cancer treated
with radiotherapy and goserlin. Patients eligible for this trial were
T1– 2 WHO grade 3, or T3– 4 any grade. In all, 415 patients were
randomised to either radiotherapy alone (50 Gy to the whole pelvis
and a prostate boost to 70 Gy) or the same radiotherapy and 3.6 mg
goserelin s.c. every 4 weeks, starting on the first day of
radiotherapy and continuing for 3 years. Patients in the latter
group also received cyproterone acetate (150 mg day1 p.o.) during
the first month of treatment to inhibit the transient rise in
testosterone associated with the administration of goserelin.
In 1997, the median follow-up was 45 months. Kaplan–Meier
estimates of the disease-free survival were 85 vs 48% (Po0.001) in
favour of the combined-treatment group. Most impressive was the
increase in overall survival: 79 vs 62% (P¼ 0.001). The EORTC trial
was updated in 2002 (Bolla et al, 2002) with a median follow-up of
66 months. The 2002 update showed that the difference in survival
between the two groups was maintained over time. The disease-
free survival was 74 vs 40% (P¼ 0.0001) and the overall survival
was 78 vs 62% (P¼ 0.0002), in favour of the combined-modality
arm.
For the EORTC trial, hormonal therapy was initiated on the first
day of radiation therapy and continued for 3 years. The concurrent
administration of hormonal therapy with radiation therapy may
allow for a synergistic effect. As the radiotherapy was delivered to
both the prostate and regional lymph nodes, the benefit of
combined hormonal-radiation therapy may have been due to
treatment of either of these areas. Investigation of the importance
of lymph node radiation vs prostate radiation was the subject of
another trial (RTOG 94-13), discussed later in this review.Received 30 October 2003; accepted 5 December 2003
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The administration of adjuvant hormonal therapy may have a
separate biologic effect from the concurrent administration of
hormonal therapy with radiation therapy. Patients eligible for the
EORTC trial had either high-grade tumour or cT3/cT4 tumour of
any grade. Multivariate analysis revealed that disease-free survival
was associated with an increased relative risk of 1.84 for WHO
grade 3 tumours (Bolla et al, 2002). The benefit seen with the long-
term use of adjuvant hormonal therapy may be due to the large
number of high-grade tumours in the trial. Tumour grade predicts
for metastatic disease, and the use of long-term adjuvant hormonal
therapy may allow for treatment of possible micro-metastatic
disease.
RTOG 85-31
RTOG 85-31 was a phase III randomised trial of radiation therapy
alone vs radiation therapy, followed by adjuvant goserelin for life.
The patient eligibility for this trial was lymph node positive, cT3 or
pT3. In both arms, the radiation therapy was 44–46 Gy to the
whole pelvis, followed by a boost to the prostate to a total dose of
65–70 Gy. Adjuvant goserelin was started during the last week of
radiation therapy and continued indefinitely or until signs of
disease progression.
Initial analysis of the data from RTOG 85-31 showed that the
adjuvant goserelin arm had a benefit in local control (84 vs 71%,
Po0.0001), a decrease in distant metastases (17 vs 30%, Po0.001)
and an increase in disease-free survival (60 vs 44%, Po0.0001), but
no difference in overall survival for all patients. However, in
patients with centrally reviewed tumours with a Gleason score (GS)
of 8– 10, the difference in 5-year overall survival was 66 vs 55%,
favouring the adjuvant goserelin arm (P¼ 0.03) (Pilepich et al,
1997). With additional follow-up (median 10 years), adjuvant
goserelin showed a benefit for all patients in the study. Adjuvant
hormonal therapy demonstrated increased local control (77 vs
61%), decreased distant metastases (25 vs 39%) and improved
overall survival (53 vs 38%) (Pilepich et al, 2003).
The fact that radiation and hormonal therapies overlap for only
1 week suggests that the improvement in overall survival seen in
this study is not due to a synergistic effect within the radiation
field. Instead, an additive effect of local treatment with radiation,
and systemic therapy with androgen deprivation, is the most likely
explanation of the observed benefit.
Similar to the EORTC trial, patients with high-grade (Gleason
8–10) tumours benefited most from long-term hormonal therapy.
This supports the idea that patients with high-grade tumours are
most likely to develop distant metastases and die from prostate
cancer, and that long-term hormonal therapy must have a
significant systemic effect in order to decrease the incidence of
distant metastases and improve the overall survival.
RTOG 86-10
RTOG 86-10 was a phase III randomised trial of external-beam
radiation therapy þ / combined androgen blockade (CAB) for
locally advanced prostate cancer patients. The eligible patients had
bulky tumours (palpable 25 cm2 or more), clinical stage T2– 4. The
standard arm received external-beam radiation therapy, 44–46 Gy
to the prostate, SV and pelvic lymph nodes, followed by a prostate
boost to 65–70 Gy. The experimental arm was the same radio-
therapy, plus goserelin and flutamide. Goserelin was given 3.6 mg
s.c. every 4 weeks and flutamide 250 mg p.o. three times a day for 2
months before and 2 months during radiation therapy.
The initial RTOG 86-10 report was published in 1995 (Pilepich
et al, 1995), with a median follow-up of 4.5 years. The publication
documented a cumulative incidence of local progression at 5 years
of 71% with radiation alone, and 45% with radiation plus short-
term CAB (Po0.001). Progression-free survival was also increased
(Po0.001) in the hormonal therapy arm: 30 vs 15% with radiation
alone. There was no difference in overall survival.
In 2001, a follow-up of this study was published (Pilepich et al,
2001), with a median follow-up of 6.7 years for all patients, and 8.6
years for living patients. The arm containing CAB was associated
with improved local control (42 vs 30%, P¼ 0.016), reduced
incidence of bone metastases (34 vs 45%, P¼ 0.04), increased
disease-free survival (33 vs 21%, P¼ 0.004), but no overall survival
advantage to the group as a whole. However, on subset analysis of
patients with a GS 2– 6, there was an overall survival advantage (70
vs 52%, P¼ 0.015).
The group of patients that benefited the most in RTOG 86-10
were patients with bulky disease and a GS of 2–6. Patients with
higher-grade tumours did not benefit, probably because they
require long-term hormonal therapy, similar to the protocol used
in the EORTC study and RTOG 85-31. Today, with widespread use
of PSA screening, we rarely see patients present with palpable
disease measuring 25 cm2. Instead, modern day bulk disease may
represent any patient with significant palpable disease on digital
rectal examination (clinical stage T2b, T2c, T3a or T3b). These
patients will most likely benefit from the use of hormonal therapy
in combination with radiotherapy.
The percentage of positive biopsies may also be used to
determine who may benefit from short-term hormonal therapy.
In a concept popularised by D’Amico, percent positive biopsies
can be an independent predictor of biochemical failure. Patients
with otherwise low-risk features may behave more like inter-
mediate-risk patients if 450% of the biopsies are positive for
cancer (D’Amico et al, 2001; D’Amico et al, 2002). These patients
with 450% positive biopsies may represent ‘bulky disease’ in
today’s PSA era and, therefore, benefit from short-term hormonal
therapy.
It is important to note that the hormonal therapy in this trial
was given as neoadjuvant and concurrent therapy, and that whole-
pelvic radiotherapy was also used. This allows for a synergistic
effect of the hormonal therapy and radiotherapy on the lymph
nodes and/or prostate. The 4-month duration of hormonal therapy
might also have a systemic effect, as there was a decrease in bone
metastasis in the hormonal therapy group. Whether there is
a difference between short-term (4 months) and long-term
(2–3 years) hormonal therapy was the question addressed by
RTOG 92-02.
RTOG 92-02
RTOG 92-02 was a prospective randomised trial testing the
duration of androgen suppression with external beam radiation
in patients with locally advanced prostate cancer (Table 1).
Eligibility included T2C–4 with PSA o150 ng ml1. All patients
received 4 months of goserelin and flutamide, 2 months before and
2 months during radiation, and then were randomised to either no
further therapy or 24 months of additional goserelin alone.
Radiation doses were 44–50 Gy to the whole pelvis and 65–
70 Gy to the prostate. This trial entered 1554 patients, and reported
results from a median follow-up of 4.8 years.
Initially published in abstract form (Hanks et al, 2000), the
group with LTAD showed a significant improvement in disease-
free survival (54 vs 34%, P¼ 0.0001), clinical local progression (6.2
vs 13%, P¼ 0.0001), freedom from distant metastasis (11 vs 17%,
P¼ 0.001) and ASTRO-defined biochemical control (21 vs 46%,
P¼ 0.0001). There was no difference in the 5-year overall survival
between the two arms (78 vs 79%).
In a subset analysis of T3, T4 and T2 with GS 8–10 (the same
criteria used for Bolla et al, 1997), LTAD showed an advantage in
disease-free survival (90 vs 86%, P¼ 0.03), but no difference in
overall survival. In the subset analysis of all GS 8 –10 patients (the
group that benefited most from hormonal therapy in RTOG 85-31),
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the 5-year overall survival (80 vs 69%, P¼ 0.02) and disease-free
survival (90 vs 78%, P¼ 0.007) were in favour of the LTAD group.
The data from RTOG 92-02 support the findings from the
EORTC trial and RTOG 85-31. Patients with high-grade (GS8–10)
tumours benefit most from LTAD. Data from all the three trials
show an increase in overall survival when patents with high-grade
tumours are treated with long-term hormonal therapy. The exact
duration of hormonal therapy is still in question. RTOG 92-02,
EORTC and RTOG 85-31 used 2 years, 3 years and unlimited years,
respectively. Since there is no evidence to support that greater than
2 years of LTAD is better than 2 years, we suggest that patients
with high-grade tumours be treated with 2 years of adjuvant
hormonal therapy.
RTOG 94-13
The eligibility for RTOG 94-13 was limited to clinically localised
adenocarcinoma of the prostate, with elevated PSA of less than or
equal to 100. Patients were stratified by T-stage, PSA and GS, and
were required to have an estimated risk of lymph node
involvement 415%, based on the equation: risk of positive
nodes¼ (2/3) PSAþ ((GS)6) 10) (Partin et al, 1993; Roach,
1993).
In RTOG 94-13, CAB was used and consisted of flutamide
250 mg p.o. t.i.d. and either leuprolide or goserelin acetate,
administered 2 months before and 2 months during radiotherapy
(N&CHT), or 4 months following the completion of radiotherapy
(adjuvant hormone therapy (AHT)). Patients were randomised to
one of four arms: arm 1 received whole-pelvic radiotherapy and
N&CHT, arm 2 received prostate only radiotherapy and N&CHT,
arm 3 received whole-pelvic radiotherapy plus AHT, and arm 4
received prostate only radiotherapy plus AHT.
With a median follow-up for all patients of 59.3 months, the
study showed that patients treated with whole-pelvic radiotherapy
experienced a 4-year progression-free survival of 56% compared to
40% for prostate only (P¼ 0.014). Comparing all the four arms,
there was a progression-free survival advantage for arm 1 (61%)
compared to the other three arms (45, 49 and 47%, respectively;
P¼ 0.008) (Roach et al, 2003). Longer follow-up is needed to
address the issue of disease-specific and overall survival. However,
even without survival data, the findings still reveal the value of
whole-pelvic radiotherapy.
Before discussing the individual arms in more detail, it is
important to mention a quirk of the study design. Patients treated
in arms 1 and 2 are subject to a worse outcome relative to arms 3
and 4, because of the timing of hormonal therapy. The time of
failure was measured from the time of randomisation. Patients in
arms 1 and 2 were treated with N&CHT and received CAB therapy
for months 1 and 2, and concurrent hormone therapy plus
radiation in months 3 and 4, so that the total duration of treatment
was 4 months. In contrast, patients treated in arms 3 and 4
received 2 months of radiation followed by 4 months of AHT, so
that their total duration of treatment was 6 months. Thus, when
measured from the time of randomisation, the patients receiving
AHT were likelier to be disease-free at least 2 months later, because
of the time at which hormone therapy was discontinued. Figure 1A
demonstrates this effect by comparing arms 2 and 4 (both
prostate-only arms) separately from the other curves. These
curves are consistent with a time-to-failure bias in favour of
AHT compared to N&CHT, of approximately 2 months. This
curve suggests that, whether hormonal therapy is given in an
N&CHT fashion or as an AHT after EBRT, there is no evidence
of a difference in biologic interactions if only the prostate is
irradiated.
Next, it is instructive to compare the two whole-pelvic arms, the
one receiving N&CHT (arm 1) and the one receiving AHT (arm 3).
Here, as with the prostate-only arms, there is a bias in favour of the
AHT arm in disease-free survival due to the timing of hormone
Table 1 Summary of five prospective randomised trials involving hormonal and radiation therapy in patients with prostate cancer
EORTC RTOG 85-31 RTOG 86-10 RTOG 92-02 RTOG 94-13
n 415 977 471 1554 1323
Eligibility T1–2, WHO
grade 3
cT3, pT3 or N1 T2–4 with palpable
tumour 25 cm2
T2c–4 PSAo150 PSAo100
T3–4,
any grade
Risk of LN
involvement415%
Median
follow-up
66 months 7.3 years (all) 6.7 years (all) 4.8 years 5 years
10 years (alive) 8.6 years (alive)
Arms XRT vs
XRT+goserelin
starting day
1 for 3 years
XRT vs XRT+adj
goserelin for life
XRT vs XRT+
CAB 2 months
before 2
months during
XRT+CAB 2
months before+
2 months during vs
same+2 years
adjuvant goserelin
WP+N&CHT
vs PO+N&CHT vs
WP+AHT vs
PO+AHT
Whole
pelvis
Yes Yes Yes Yes Yes
Arms 1 and 3
Dose 50 Gy wp 44–46 Gy wp 44–46 Gy wp 44–50 Gy wp 50.4 wp
70 Gy
prostate
65–70 Gy p 65–70 Gy p 65–70 Gy p 70.2 po
Local-regional
control
72 vs 97% 61 vs 77% 42 vs 30% 94 vs 87% NR
Distant
mets
56 vs 22% 39 vs 25% 34 vs 45% 11 vs 17% NR
Disease-free
survival
40 vs 74% NR 33 vs 21 % 54 vs 34% 60 vs 44 vs
49 vs 50%
Overall
survival
62 vs 78%
all patients
38 vs 53%
all patients
70 vs 52% for
GS 2–6
80 vs 69% for
GS 8–10
NR
P-value 0.0002 o0.0043 0.015 0.007
CAB¼ combined androgen blockade; GS¼Gleason score; AHT¼ adjuvant hormone therapy; NR=not reported.
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therapy. Despite this bias, the curves overlap in the early part of
the curve, but separate with longer follow-up (Figure 1B). This
suggests that there is a greater biologic interaction when hormonal
therapy is given before and during, rather than after, whole-pelvic
radiotherapy.
Additional evidence for the benefits of whole-pelvic radio-
therapy is seen in the comparison of arms 1 and 2, both using
N&CHT (Figure 1C). Arm 1 included the whole pelvis, while arm 2
included only prostate. This comparison eliminates the biases
associated with AHT and demonstrates a very large effect of whole-
pelvic treatment. This was further supported by comparing arms 3
and 4, both of which used AHT (arm 3 including whole-pelvic
treatment and arm 4 prostate-only radiotherapy) (Figure 1D). This
curve suggests that there is no evidence of benefit to whole-pelvic
radiotherapy if given with AHT. This very important observation
suggests that the location of the biologic interaction is in the pelvic
lymph nodes. The data from RTOG 94-13 clearly demonstrate that
hormonal therapy given short term before and during radio-
therapy enhances the biologic effect of whole-pelvic radiation
treatment.
RTOG META-ANALYSIS
A meta-analysis of RTOG 7506, 7706, 8531 and 8610 confirms the
above observations of the advantage of hormonal therapy with
radiation therapy. A total of 2742 men with prostate cancer were
separated into four risk groups that are predictive of disease-free
survival (Roach et al, 2000a). Group 1 patients are T1–2 and
GS 2–6; group 2 are T3 GS 2 –6 or T1–2 GS 7; group 3 are T3 GS 7
or T1– 2 GS 8– 10; group 4 are T3 GS 8 –10. All patients were
treated in the pre-PSA era; therefore, PSA was not used to define
the risk groups. Patients in risk group 2 (either GS 2 –6 with bulky
tumours, or GS 7 with organ-confined disease) benefited from 4
months of flutamide and goserlin. Patients in risk groups 3 and 4
(T3 GS 7 or GS 8 –10) benefited from long-term hormonal therapy
(Roach et al, 2000b).
FINAL RECOMMENDATIONS
Currently, the use of hormonal therapy falls into two categories:
short-term and long-term hormonal therapy. The short-term
category involves hormonal therapy 2 months before and 2
months during radiation. The long-term category involves short-
term hormonal therapy plus 2 years of adjuvant hormonal therapy.
Patients who should be considered for short-term hormonal
therapy include patients with a risk of lymph node involvement
415%, or patients with bulky disease defined by either a large
palpable mass in the prostate or 450% positive biopsies or T3
disease. It is important to remember that the benefit of short-term
hormonal therapy is only seen when given with whole-pelvic
radiation therapy. The patients who should be considered for long-
term hormonal therapy are those with either GS 8– 10 tumours or
possibly T3 GS 7.
FUTURE DIRECTIONS
There are a couple of current RTOG trials that are continuing to
investigate the role of hormonal therapy for patients with prostate
cancer. For intermediate-risk patients, there is RTOG 99-10, a
phase III randomised trial comparing standard treatment (8 weeks
neo-adjuvant CAB and 8 weeks concurrent CAB/XRT), with the
experimental arm of 28 weeks neo-adjuvant CAB and 8 weeks
concurrent CAB/XRT. The radiotherapy is identical in both arms.
Whole-pelvic radiation is used for those patients with a risk of
lymph node involvement 415%. RTOG 99-10 will address if
longer neo-adjuvant CAB is beneficial in intermediate-risk
patients.
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Figure 1 Progression-free survival for the four arms of RTOG 94-13.
(A) POþN&CHT vs POþAHT. (B) WPþN&CHT vs WPþAHT. (C)
WPþN&CHT vs POþN&CHT. (D) WPþAHT vs POþAHT (modified
with permission from Roach et al, 2003).
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For high-risk patients, there is RTOG 99-02. The standard
arm in this trial is 2 months neo-adjuvant CAB, 2 months
concurrent CAB/XRT plus 2 years of adjuvant LHRH agonist.
The experimental arm involves the same therapy, plus
adjuvant chemotherapy consisting of Emcyt, Toxol and Etoposide.
This trial is addressing the question of whether additional
chemotherapy can reduce the incidence of distant
metastasis, which might improve survival in this high-risk
population.
Much progress has been made in the treatment of prostate
cancer over the past 6 years. With subsequent follow-up of past
trials and completion of current trials, we will increase our
knowledge of how to optimally treat prostate cancer patients with
the combination of hormonal therapy and radiotherapy.
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